The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
continued...
17/08/2020 Clarification Regarding Medusa 19 Antibody Test
11/08/2020 Therapeutics Chief Development Officer Appointment
07/08/2020 SARS-CoV-2 Antigen Test Clinical Collaboration
06/08/2020 COVID-19 Rapid Antigen Test Manufacturing Partner
29/07/2020 Expanded Partnership with Daewoong Pharmaceutical
22/07/2020 Update on Adeptrix COVID-19 Diagnostic Test
13/07/2020 Collaboration with Integumen plc
24/06/2020 Update on COVID-19 Test Development Partnership
18/06/2020 Update on Affimer® Therapy for COVID-19 Infection
09/06/2020 Update on COVID-19 Test Development with Adeptrix
04/06/2020 Result of Fundraising
A post of fact and indisputable truth. No opinion, no conjecture.
June '20 Avacta raised £48M (£38 Therapeutics, £10M Diagnostics) via the issue of 40M ordinary shares (price £1.20). Current cash position £27M - runway until H2 '23 without any other income taken into account - source Avacta investor presentation - https://bit.ly/3Jq3qGv
Since the placing Avacta have issued the following statements via RNS (excluding director dealing, price monitoring and AGM notices) - Split over 2 posts as there so many!
03/02/2022 Dose escalation in the phase I trial of AVA6000
18/01/2022 Second pre|CISION Pro-drug Candidate Selected
10/01/2022 Update on AffiDX and detection of Omicron variant
22/12/2021 AffiDX Receives CE Mark for Consumer Self-Testing
15/12/2021 AffiDx® lateral flow test detects Omicron variant
29/11/2021 FDA Approval of IND Application for AVA6000
02/11/2021 Update on UK Availability of AffiDX Test
29/09/2021 Development Milestone in LG Chem Partnership
06/09/2021 New appointments to Scientific Advisory Board
02/09/2021 Appointment of Chief Scientific Officer
11/08/2021 First Patient Dosed in AVA6000 Phase 1 Trial
04/08/2021 Update on AffiDX Lateral Flow Test
14/07/2021 Diagnostics achieves ISO 13485 Certification
29/06/2021 AffiDX Lateral Flow Test Detects Delta Variant
21/06/2021 AffiDX Lateral Flow Test Distribution Agreement
06/09/2021 New appointments to Scientific Advisory Board
02/09/2021 Appointment of Chief Scientific Officer
11/08/2021 First Patient Dosed in AVA6000 Phase 1 Trial
04/08/2021 Update on AffiDX Lateral Flow Test
14/07/2021 Diagnostics achieves ISO 13485 Certification
29/06/2021 AffiDX Lateral Flow Test Detects Delta Variant
21/06/2021 AffiDX Lateral Flow Test Distribution Agreement
11/06/2021 Registration of AffiDX Lateral Flow Test in EU
07/06/2021 MHRA Confirms Registration of Lateral Flow Test
01/06/2021 Update on Lateral Flow Test Regulatory Submissions
10/05/2021 AffiDX SARS-CoV-2 Antigen Lateral Flow Test Update
20/04/2021 Clinical validation of AffiDX Lateral Flow Test
06/04/2021 Distribution Agreement with ABCAM plc
09/03/2021 Diagnostic Licensing Deal with Biokit
08/03/2021 Rapid Antigen Test Detects SARS-CoV-2 Variants
18/02/2021 Phase I CTA for AVA6000 Approved by MHRA
16/02/2021 Results of Initial Evaluation of SARS-CoV-2 LFT
08/02/2021 Commercial Partnership with Mologic
01/02/2021 AffyXell $7.3 Million Series A Financing
28/01/2021 Collaboration Agreement with Bruker
07/01/2021 License Agreement with POINT Biopharma Inc.
23/12/2020 Submission of CTA for AVA6000 Pro-doxorubixin
21/12/2020 License Agreement with Astrea Bioseparations
23/11/2020 SARS-CoV-2 Rapid Antigen Test Update
30/09/2020 Launch of SARS-CoV-2 BAMS Research Test
24/09/2020 Update on Integumen Collaboration
07/09/2020 Avacta to Launch SARS-CoV-2 ELISA Laboratory Test
02/09/2020 Expansion of COVID-19 Test Manufacturing Capacity
18/08/2020 Expanded Partnership with LG Chem Li
There are a number of false statements being posted by individuals on this board with the sole purpose of driving the price in their favour.
Please don't engage with them but report them to LSE and mention that the statements are potentially libellous. LSE must deal with them or they themselves can be dragged into any potential defamation case.
Enough is enough
I'm not even going to bother reading the BB today as it will be full of sanctimonious trolling twats.
Bad day for my AVCT holding - however my take-away is that FDA will apply scrutiny to current testing crop and come to similar conclusion re omicron sensitivity. UK government will ignore their finding as per Innova debacle - SNAFU
AVCT fix the broken piece (antibody) in the LFT and press on - guess a few weeks or so delay.
AVCT playing everything with a straight bat - which in my experience wins out in the long-tun
At least I get an opportunity to get my average down a bit :-)
Ignore the trolls and don't wet the bed re. LFT which is a side hustle for the main AVCT therapeutics event
https://www.bbc.co.uk/news/health-59895258
Worth a read
Peter Whitehurst has links with Richard Hughes (Zeus and Medusa) - see shareholders of ARCIS BIOTECHNOLOGY HOLDINGS LIMITED
blast from the past in addition to the info shared here - https://bit.ly/31WZc93
Just because I know they're lurking on this board. Bishop5022 (https://bit.ly/3q8qkdB) from twitter has been reported for defamation to Avacta. These people need to understand there are consequences to their actions and they cannot hide behind anonymous accounts. Unless they've used mechanisms to conceal their identity which would require a level of sophistication which, from reading their posts, I suspect they don't possess.
Every account that is activity engaged in pushing the false narrative on here should be subject to the same. It is unacceptable to defame a company (and an individual) simply to drive the price down.
Utterly fed-up with the constant targeted attacks on this company by a few individuals.
Sealions need not respond - you'll be straight in the bin
I wonder if we should put together a twitter account like https://bit.ly/3pUbSaj for AVCT? we have a fair few posts where facts are shared - thank goodness!- worth collating?
unless such a thing already exists!
To keep this on-topic - great post by TheEthicalTout on twitter too - a sage reminder of where the real value is for Avacta share-holders
expect https://bit.ly/2Zhjyc1 to be updated tomorrow